Sino Biopharmaceutical (SBMFF) Projected to Post Quarterly Earnings on Thursday

Sino Biopharmaceutical (OTCMKTS:SBMFF) is anticipated to issue its results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of $0.0086 per share and revenue of $2.0675 billion for the quarter.

Sino Biopharmaceutical Stock Performance

OTCMKTS SBMFF opened at $0.83 on Thursday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.28 and a current ratio of 1.36. Sino Biopharmaceutical has a 52-week low of $0.44 and a 52-week high of $1.24. The company has a 50-day simple moving average of $0.85 and a 200 day simple moving average of $0.91.

Sino Biopharmaceutical Company Profile

Sino Biopharmaceutical Limited (OTCMKTS: SBMFF) is a Hong Kong–incorporated investment holding company principally engaged in the pharmaceutical sector. Founded in 2000 and listed on the Hong Kong Stock Exchange in 2006, the company has developed an integrated business model that spans research and development, manufacturing and commercialization of healthcare products. Through its subsidiaries, Sino Biopharmaceutical focuses on enhancing China’s domestic pharmaceutical infrastructure while expanding its footprint across key therapeutic areas.

The company’s product portfolio is organized into three core segments: infusion solutions, small-molecule synthetic pharmaceuticals and innovative biologics.